(Q46664324)

English

The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo

scientific article published on 26 March 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18388877

The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo (English)

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18388877

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18388877

object named as

A Tornio

1

0 references

object named as

M Neuvonen

3

0 references

author name string

J Laitila

4

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18388877

A Kalliokoski

5

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18388877

P J Neuvonen

6

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18388877

J T Backman

7

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18388877

language of work or name

0 references

publication date

26 March 2008

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18388877

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18388877

84

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18388877

3

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18388877

403-411

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18388877

https://scigraph.springernature.com/pub.10.1038/clpt.2008.34

0 references

Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

21 January 2018

Clinical pharmacokinetics and pharmacodynamics of repaglinide

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclosporine markedly raises the plasma concentrations of repaglinide

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemfibrozil greatly increases plasma concentrations of cerivastatin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma concentrations of active simvastatin acid are increased by gemfibrozil

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Rofecoxib Is a Potent, Metabolism-Dependent Inhibitor of CYP1A2: Implications for in Vitro Prediction of Drug Interactions

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic drug interactions of macrolides

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.34

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CLPT.2008.34

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18388877

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18388877

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46664324&oldid=2125127942"